PDF herunterladen
Semin Respir Crit Care Med
DOI: 10.1055/a-2704-6851
Invited Review Article

Glucocorticoid Treatment in Community-Acquired Pneumonia

Authors

  • Pierre-François DEQUIN

    1   Faculty of Medicine, INSERM UMR 1100 Centre d'Etude des Pathologies Respiratoires, University of Tours, Tours, France (Ringgold ID: RIN27092)
    2   Médecine Intensive - Réanimation et Centre d'Investigation Clinique INSERM CIC-P 1415, Centre Hospitalier Régional Universitaire de Tours, Tours, France (Ringgold ID: RIN26928)
    3   CRICS-TriGGERSep F-CRIN network, Strasbourg, France

  • Marco Confalonieri

    4   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy (Ringgold ID: RIN9315)
    5   Pulmonology Unit, University Hospital of Cattinara, Trieste, Italy
Weitere Informationen
 als PDF herunterladen
Preview

Despite a fairly large number of comparative trials (which are, however, very heterogeneous), the role of corticosteroids in the adjuvant treatment of community-acquired pneumonia remains controversial. Nevertheless, recent randomized trials with adequate power in ICU patients, albeit with conflicting results, have contributed to clarifying our understanding of this issue. More accurate phenotyping of patients likely to benefit from corticosteroid treatment must now be carried out. In COVID-19 pneumonia, their benefit is not in question. For certain specific pathogens, including viral pathogens, their indications must be refined. They are still not recommended for influenza. They appear generally safe for short-term use in select populations.



Publikationsverlauf

Eingereicht: 08. Juli 2025

Angenommen nach Revision: 17. September 2025

Accepted Manuscript online:
18. September 2025

© . Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA